Companies › Chiesi Farmaceutici
10 active drug programs in 17 registered trials: 8 Phase 2, 5 Phase 3, 3 Phase 1, 1 Phase 4; Respiratory, Other, Metabolic and endocrine, Psychiatry; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Formoterol Beta-2 adrenergic receptor agonist | ADRB2 | Phase 4 | Asthma | Jun 2028 |
| Metreleptin Leptin receptor agonist | LEPR | Phase 3 | Partial Lipodystrophy; Familial Partial Lipodystrophy; Lipodystrophy; Anorexia Nervosa … | Mar 2028 |
| CHF 5993 100/6/12.5 μg pMDI HFA-152a Triple combination of inhaled corticosteroid, long-acting beta-2 agonist, and long-acting | ADRB2, CHRM3 | Phase 3 | Asthma | Oct 2028 |
| Oleogel-S10 Topical gel containing plant-based ingredients for wound healing | – | Phase 3 | Epidermolysis Bullosa | Sep 2029 |
| CHF5993 pMDI 100/6/12.5 µg with HFA-152a Triple combination: inhaled corticosteroid (ICS), long-acting beta-2 agonist (LABA), long- | ADRB2, CRHR1 | Phase 2 | Asthma | Jun 2027 |
| PRX-102 Recombinant human alpha galactosidase-A (pegunigalsidase alfa) | GLA | Phase 2 | Fabry Disease | Oct 2027 |
| CHF10067 (Zampilimab) TNF-α inhibitor monoclonal antibody | TNF | Phase 2 | Idiopathic Pulmonary Fibrosis | Jun 2028 |
| CHF6467 | – | Phase 1 | Healthy Volunteers | Feb 2027 |
| CHF10136 | – | Phase 1 | Asthma | Dec 2027 |
| CHF6333 | – | Phase 1 | Bronchiectasis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05164341 | Metreleptin | Phase 3 | Partial Lipodystrophy | Metabolic and endocrine | Jul 2026 |
| NCT06166056 | CHF6333 | Phase 1 | Bronchiectasis | Respiratory | Aug 2026 |
| NCT06305182 | Metreleptin | Phase 2 | Anorexia Nervosa | Psychiatry | Dec 2026 |
| NCT07163182 | CHF6467 | Phase 1 | Healthy Volunteers | Other | Feb 2027 |
| NCT07301736 | CHF5993 pMDI 100/6/12.5 µg with HFA-152a | Phase 2 | Asthma | Respiratory | Jun 2027 |
| NCT02262832 | Metreleptin | Phase 3 | Lipodystrophy | Metabolic and endocrine | Jul 2027 |
| NCT02262806 | Metreleptin | Phase 2 | Diabetes | Metabolic and endocrine | Jul 2027 |
| NCT05710692 | PRX-102 | Phase 2 | Fabry Disease | Metabolic and endocrine | Oct 2027 |
| NCT07851623 | CHF10136 | Phase 1 | Asthma | Respiratory | Dec 2027 |
| NCT06679270 | Metreleptin | Phase 3 | Familial Partial Lipodystrophy | Metabolic and endocrine | Mar 2028 |
| NCT07666490 | Formoterol | Phase 4 | Asthma | Respiratory | Jun 2028 |
| NCT07516951 | CHF10067 (Zampilimab) | Phase 2 | Idiopathic Pulmonary Fibrosis | Respiratory | Jun 2028 |
| NCT06328608 | PRX-102 | Phase 2 | Fabry Disease | Metabolic and endocrine | Oct 2028 |
| NCT05351164 | Metreleptin | Phase 2 | Lipomatosis, Multiple Symmetrical | Metabolic and endocrine | Oct 2028 |
| NCT07546981 | CHF 5993 100/6/12.5 μg pMDI HFA-152a | Phase 3 | Asthma | Respiratory | Oct 2028 |
| NCT06917690 | Oleogel-S10 | Phase 3 | Epidermolysis Bullosa | Other | Sep 2029 |
| NCT00085982 | Metreleptin | Phase 2 | Severe Insulin Resistance | Metabolic and endocrine | Jan 2030 |
Teva Branded Pharmaceutical Products R&D Valenta Pharm JSC Shanghai Synvida Biotechnology Shionogi Vicore Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.